Nanollose Limited Overview
Nanollose is a pre-revenue Western Australian advanced-biomaterials company. It is commercialising microbial (bacterial) cellulose as a non-forestry feedstock for the US$20bn-plus man-made cellulosic fibre (MMCF) industry. Its process ferments food and agricultural waste streams into cellulose that is more than 99% pure, in days rather than decades. That cellulose is processed into a pulp that can be fed directly into existing lyocell lines alongside wood pulp, producing its flagship Nullarbor™ "Forest-Friendly" fibre. After a FY2026 strategic review under new CEO Andrew Moullin, the company narrowed its focus from a multi-product platform (textile fibre, nonwoven fibre, horticultural gel, leather alternative) to Nullarbor alone. It now intends to build and control a single Pilot Facility in Western Australia, generate industrial-grade process data, and monetise the process through licensing, joint venture or sale to incumbent fibre producers rather than building its own industrial capacity. The company has a market capitalisation of about A$20m, A$1.33m of cash (30 June 2026), and a going-concern material uncertainty.
Company's own description (FY2026 Annual Report, paraphrased). The company calls itself an advanced biomaterials company working to commercialise technology that creates fibres, fabrics and other materials from microbial cellulose. In FY2026 its principal activities were research and development and the work needed to scale its microbial cellulose technologies. After a portfolio review completed during the year, the company narrowed its primary near-term focus to the development, scale-up and commercialisation of Nullarbor™, its Forest-Friendly MMCF for textiles.
How the technology works. Wood contains less than 50% cellulose, so dissolving pulp requires large-scale logging and chemical pulping. Nanollose instead uses a fermentation process, which the company likens to brewing kombucha. Bacteria convert food waste, agricultural waste and by-products (sugar, wine, beer and coconut-water streams have been referenced historically) into microbial cellulose (MC) that is more than 99% pure. The MC is grown in trays over about 10–15 days by contract partner Hainan Guangyu Biotechnology (HGB) in Haikou, China. It is then purified, dewatered and processed into a pulp. In the lyocell route, that pulp is co-dissolved with FSC-certified wood pulp in N-methylmorpholine N-oxide (NMMO) solvent and spun on standard lyocell equipment at partner Birla Cellulose in India. The resulting fibres are named by MC content (Nullarbor-20, -25 and -30 contain 20%, 25% and 30% MC respectively).
Business model. The intended model is technology monetisation, not manufacturing at scale. Management's FY2026 letter says the asset is "the process, not the Pilot Plant." The company plans to prove the process at a scale the industry recognises, then deploy it inside existing third-party plants through:
-
licence (royalty on third-party tonnes);
-
joint venture; or
-
outright sale of the technology and know-how.
Revenue model mix. There is currently no operating revenue.
Value-chain position. Nanollose sits upstream as a feedstock and process-technology provider.
Customer types and end-markets. The target customers are MMCF producers (lyocell, viscose and modal makers), who would buy pulp or license the process. The secondary "pull" audience is fashion and textile brands with deforestation-free or traceability commitments. Historic or deprioritised end-markets are hygiene and wet-wipe nonwovens (Nufolium), vertical-farming and microgreens horticulture (Biollose MicroGel / Jelli Grow), and leather-alternative materials.
Independent characterisation. Nanollose is best understood as an early-stage, single-asset, pre-commercial process-technology company. Its value rests on three things:
-
whether a laboratory-scale process improvement (at least 80% efficiency gain, one production stage removed, announced April 2026) holds at pilot scale;
-
whether a self-built Western Australian Pilot Facility can be funded from a A$1.3m cash base and a roughly A$20m market capitalisation without severe dilution; and
-
whether a major MMCF producer, most plausibly existing partner Birla Cellulose, will sign a commercial licence.
The "drop-in feedstock" positioning is a genuine strategic merit. Nanollose does not ask the industry to scrap existing lyocell assets, unlike some next-generation fibre rivals that require new spinning technology. The company has now completed four pilot spins over four years (2022–2026) without a binding offtake.
Strategy
Stated strategy themes (FY2026 Annual Report and the 8 April 2026 CEO letter, paraphrased)
-
Single flagship focus. Concentrate scarce capital and technical resources on Nullarbor™ fibre. Biollose, leather-like materials and Nufolium remain in the IP portfolio but are off the near-term agenda.
-
Complement the incumbents, don't compete with them. Nullarbor is designed as an incremental, fungible feedstock for existing lyocell lines, which lowers adoption barriers. The company does not intend to build industrial MMCF capacity.
-
Monetise the process. Value creation is through licence, joint venture or sale to major producers. Management highlights that licence income scales on other parties' capital and customers.
-
Build and control a single Western Australian Pilot Facility. This replaces the earlier two-stage (pilot plus demonstration line), capital-light, partner-backed model described in the March 2026 quarter. The rationale is speed of iteration, control over pace, protection of know-how, and lower total pre-revenue operating cost.
-
Onshore capability. Analytical, testing and process-development work moves to Australia, which may also unlock Australian non-dilutive R&D grants (an advisor has been engaged).
-
Staged procurement. Capex is to be committed progressively as each stage is specified. The overall funding approach is not yet determined.
-
Tailwinds from regulation and brand commitments. The EU Deforestation Regulation (EUDR) and brand commitments to traceability and non-forest feedstocks are cited as demand drivers.
Initiative register (last 24 months)
| Initiative | Date | Description | Status |
|---|---|---|---|
| Strategic capital raise (placement, rights issue, director fee conversion) | Dec 2024 – May 2025 | About A$2.1m (A$672k placement, A$1.05m rights issue, A$400k fee-to-equity) with attaching options | Completed |
| Paradise Textiles JV (non-binding) | Jul 2024 | Joint development and commercialisation of Nullarbor yarns and fabrics | Ongoing; fourth-spin fibre with Paradise for conversion |
| Waverley Mills blanket project | Apr 2025 | First finished consumer product (about 70 blankets) | Completed; exhibited at NGV |
| Nufolium/Magnera/Codi wipes trial | 2024 – Jul 2025 | 110kg fibre converted into nonwoven rolls and wipes | Completed; programme deprioritised |
| CEO appointment and executive restructuring | Jul 2025 | Moullin as CEO/MD; Best refocused on technology and R&D | Completed |
| Fiftyone Capital option commitment and advisory mandate | Aug 2025 | A$750k in three tranches; corporate advisory (12 months) | Completed (tranches received Sep 2025 – Mar 2026) |
| Portfolio strategic review | FY2026 H1 | Narrowed focus to Nullarbor | Completed |
| Fourth pilot spin | Feb 2026 | 580kg of fibre; first spin with no Birla pre-processing | Completed |
| Process-efficiency programme | Mar – Apr 2026 | At least 80% efficiency gain; one stage removed (laboratory scale) | Completed at lab scale; pilot validation pending |
| Pilot Facility (Western Australia) | Apr 2026 – ongoing | Global equipment tender; site selection; staged procurement | In progress; cost not disclosed |
| Onshoring of analytics and testing | Jun-2026 quarter – ongoing | Laboratory equipment delivered to Western Australia | In progress |
| Engineering team build-out | Jun – Aug 2026 | Nardini (Ops & Engineering), Hillier and Brown (consultants) | Completed hires; further consultants in discussion |
| Non-dilutive grant pursuit | FY2026 – FY2027 | Australian R&D grants tied to onshore activity | In progress |
| Cost discipline | Mar – May 2026 | Chairman salary cut of about 58%; non-executive fee cut of about 42% | Implemented |
ESG/sustainability commitments
These are product-intrinsic and not formal targets. The company positions Nullarbor as reducing reliance on logging, citing Canopy's estimate that more than 300 million trees are logged a year for fashion. No corporate emissions targets have been published.
Management targets and guidance
FY2027 operating "markers" (CEO letter, FY2026 Annual Report):
-
Secure and fit out Western Australian premises.
-
Complete the equipment tender and costing, and disclose the facility's cost and output.
-
Install and commission onshore equipment.
-
Complete larger-volume dewatering and washing trials and finalise specifications.
-
Build, commission and run the Pilot Facility.
-
Use its output to convert partner evaluations into formal commercial agreements.
There is no financial guidance (revenue, EBITDA or capex) and no medium-term financial targets.
Products & Services
The single reporting segment is organised here by technology programme.
Nullarbor™ Forest-Friendly lyocell/rayon fibre (flagship)
| Attribute | Detail |
|---|---|
| Description | Man-made cellulosic fibre produced by co-dissolving Nanollose microbial-cellulose pulp with FSC-certified wood pulp in a conventional lyocell process. It is positioned as an "incremental, fungible feedstock" for existing lyocell lines |
| Variants | Nullarbor-20 (20% MC; 250kg first pilot spin, 2022; 50kg used for Waverley Mills blankets, FY2025). Nullarbor-25 (25% MC; 425kg, fourth spin, Feb 2026). Nullarbor-30 (30% MC; 155kg, fourth spin, Feb 2026). The long-term aspiration since 2022 has been a staged scale-up toward 100% tree-free fibre |
| Key specifications/claims | A joint Birla/Nanollose patent application (Jan 2021) claimed a lyocell fibre finer than silk and significantly stronger than conventional wood-pulp lyocell (company statement). The fourth spin validated MC entering Birla's process with no extra pre-processing by Birla |
| Production partners | MC from HGB (Haikou, China); spinning by Birla Cellulose (India); yarns and fabrics by Paradise Textiles (India) and Waverley Mills (Australia) |
| Target customers | MMCF producers (licensees); premium fashion and textile brands (demand pull) |
| Launch/latest version | First fibre 2017 (viscose route); lyocell pilot 2022; latest grades Feb 2026 |
| Pricing model | Not publicly disclosed; target model is licensing/royalty |
| Flagship showcases | Lee Mathews-designed garment (Première Vision Paris 2022; NGV 2025); merino/Nullarbor blankets (Waverley Mills, 2025); "Circular in the Square" (Perth). A high-profile international brand requested a 50kg specialised fibre grade in the June 2026 quarter, which management cautions may not be delivered in the short term |
Nanollose microbial-cellulose pulp (enabling intermediate; future licensable product)
| Attribute | Detail |
|---|---|
| Description | Purified, dewatered MC pulp suited to lyocell dissolution. This is the output of the planned Western Australian Pilot Facility |
| Process status | Laboratory process at least 80% more efficient than the fourth-spin method, with one stage removed and better uniformity (22 Apr 2026). Dewatering pathway validated with a local consultant; washing validated with a European equipment supplier; initial equipment trials in the UK; dissolution validation in India in progress |
| Target capacity | Enough pulp to support "multiple tonnes" of Nullarbor fibre per month (FY2026 Annual Report). Capex not yet determined |
| Pricing | — |
Nufolium™ (nonwoven fibre)
| Attribute | Detail |
|---|---|
| Description | Tree-free rayon/lyocell-type fibre for nonwoven applications, chiefly wet wipes |
| Key milestone | 110kg of Nufolium-20 supplied to Glatfelter (now Magnera Corp., NYSE: MAGN), converted to nonwoven rolls (reported 2 Jul 2025) and shipped to Codi Group (European wipes maker supplying more than 40 countries) for sample wipes. Initial feedback was described as encouraging (FY2025 Annual Report) |
| Target customer | Hygiene and personal-care wipe manufacturers |
| Status | Deprioritised after the FY2026 strategic review |
Biollose™ MicroGel / Jelli Grow (horticultural media)
| Attribute | Detail |
|---|---|
| Description | MC-based hydrogel seed-germination and growing medium; an alternative to soilless substrates such as rockwool or coir for vertical farming and microgreens |
| Key milestones | Jelli Grow second patent grant (c. 2022). FY2025 trials with Greenspace (microgreens). Formulation refinements at HGB. Biollose national-phase patent filings in 12 jurisdictions (Jan 2026) |
| Revenue | Small historic sales (part of A$38.1k FY2023 and A$12.5k FY2024 sales revenue; split not disclosed) |
| Status | IP maintained; not a near-term focus |
Leather-like nonwoven material
| Attribute | Detail |
|---|---|
| Description | Animal-free, plastic-free biobased nonwoven positioned against bovine leather and petroleum-based "vegan leather" |
| Key milestone | Collaboration with South Metropolitan TAFE produced a haute-couture garment shown at Fremantle Design Week (FY2025) |
| Status | IP maintained; not a near-term focus |
Financial Narrative
Basis: audited statutory accounts (AASB/IFRS), FY2022–FY2026, A$. Third-party aggregators (TipRanks) present Nanollose data on a mislabelled calendar-year basis; those figures are not used here.
Income statement
Table 6.1: Income statement (A$ thousand)
Sources: FY2026 Annual Report (five-year summary; P&L); FY2025 Annual Report (P&L). The FY2021 comparatives were a net loss of A$931.0k, EBITDA of A$-875.9k and EPS of -0.77c (FY2025 Annual Report).
Note on share-based payments: the FY2024 figure is a reversal (credit). The FY2026 figure is mainly CEO options (A$518k) and performance rights (A$55k).
Margins and growth. Gross, operating, EBITDA and net margins are not meaningful while sales revenue is nil or immaterial. The five-year revenue CAGR is not meaningful (base of zero).
Operating expense detail
Table 6.2: FY2025 vs FY2026 expense breakdown (A$ thousand; FY2026 Annual Report, with restated FY2025 comparatives)
Commentary. Losses have been remarkably stable in absolute terms (A$1.1–1.6m a year from FY2021 to FY2025), which reflects a deliberately lean cost base. FY2026 is an inflection: the reported loss rose 68% to A$2.39m. Most of the increase (A$632k) is non-cash share-based payments tied to the new CEO's package. Excluding share-based payments, the loss rose about A$336k (24%). Management attributes this to process-development work after the fourth spin, onshoring of analytics, and new engineering and operations capability. The corporate employee-benefits line rose 84% because FY2026 carried a full-time CEO (A$258k cash salary) alongside the Executive Chairman (A$242k). From 1 May 2026 the chairman's salary was cut to A$112,500 and a non-executive director's fee from A$60k to A$35k (effective 1 March 2026). That partially offsets the step-up from FY2027.
Balance sheet
Table 6.3: Balance sheet (A$ thousand, at 30 June)
Sources: FY2025 and FY2026 Annual Reports (statements of financial position and changes in equity). FY2023 cash is the FY2024 opening balance. Net debt is negative, meaning a net cash position.
Commentary. The balance sheet is almost entirely cash. Internally generated IP (15 granted patents, 8 trademarks) is expensed and carries no book value, so the A$1.2m equity understates any economic value of the IP. At 30 June 2024 the company had a deficiency in equity of A$224k; the FY2025 recapitalisation and the FY2026 option conversions restored positive equity. A A$200k short-term borrowing drawn in the December 2025 quarter (believed to be an R&D-incentive-style advance; terms not disclosed) was repaid in full. No lease liabilities remain because the Nedlands lease expired on 25 November 2025.
Cash flow
Table 6.4: Cash flow (A$ thousand)
Sources: FY2025 and FY2026 Annual Reports (statements of cash flows).
Commentary. FY2026 operating outflow of A$1.80m included about A$350k of FY2025 liabilities settled in July 2025, so the underlying cash burn was about A$1.45m. Capex has been nil for three years. That will change materially once Pilot Facility procurement begins in FY2027. Funding has come wholly from equity (placements, rights issues, option exercises) and the R&D Tax Incentive.
Ratios
Table 6.5: Key ratios
ROE in FY2024–FY2025 is not meaningful because of negative or near-zero average equity. ROA and ROE use average balances. The following ratios are not meaningful for a pre-revenue company with no EBITDA, interest-bearing debt or trading working capital: ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle.
Trend synthesis. The financial trajectory is one of survival funding, not operating improvement:
-
Cumulative accumulated losses reached A$14.6m by June 2026 against A$11.3m of issued capital.
-
The share count rose 2.4× between FY2024 and FY2026 (172m to 409m).
-
The key inflection is prospective. FY2027 will be the first year with meaningful capital expenditure (Pilot Facility), and management has explicitly said the full programme will require capital beyond existing cash.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment sales revenue (AUD K) | 12.5 | 0 | 0 |
Segment total income incl. R&D incentive and interest (AUD K) | 308.5 | 243.5 | 314.6 |
Segment EBITDA (AUD K) | -1,103.2 | -1,358.0 | -2,371.6 |
Segment EBIT (AUD K) | -1,139.1 | -1,393.8 | -2,386.2 |
Segment pre-tax result (AUD K) | -1,156.6 | -1,426.5 | -2,394.0 |
Contribution to total revenue (%) | 100 | 100 | 100 |
Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
YoY change in pre-tax loss (%) | -14.1 | 23.3 | 67.8 |
Capital Programmes
| Programme | Status after FY2026 strategic review |
|---|---|
Nullarbor™ (textile lyocell/rayon fibre) | Sole flagship; all capital directed here |
Nufolium™ (nonwoven fibre for wipes) | Reported milestone July 2025; not a near-term focus |
Biollose™ / MicroGel / Jelli Grow (horticulture) | IP maintained; not a near-term focus |
Leather-like nonwoven material | IP maintained; not a near-term focus |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Sales revenue (AUD K) | 0 | 38.1 | 12.5 | 0 | 0 |
R&D tax incentive income (AUD K) | — | — | 280.3 | 231.6 | 311.1 |
Total income incl. interest and other (AUD K) | — | — | 308.5 | 243.5 | 314.6 |
EBITDA (AUD K) | -1,505.1 | -1,324.8 | -1,103.2 | -1,358.0 | -2,371.6 |
EBIT (AUD K) | -1,570.1 | -1,361.6 | -1,139.1 | -1,393.8 | -2,386.2 |
Pre-tax income (AUD K) | -1,566.5 | -1,345.7 | -1,156.6 | -1,426.5 | -2,394.0 |
Net income (AUD K) | -1,566.5 | -1,345.7 | -1,156.6 | -1,426.5 | -2,394.0 |
Share-based payments expense (AUD K) | — | — | -21.7 | 40.0 | 672.0 |
Net loss excl. share-based payments (AUD K) | — | — | -1,178.3 | -1,386.5 | -1,722.0 |
EPS basic (A$ cents) | -1.05 | -0.90 | -0.72 | -0.69 | -0.72 |
EPS diluted (A$ cents) | -1.05 | -0.90 | -0.72 | -0.69 | -0.72 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Expense line
| Expense line | FY2025 | FY2026 | YoY change (%) |
|---|---|---|---|
Research expenses (incl. R&D staff) | 695.8 | 817.8 | 17.5 |
– of which R&D employee costs | 409.3 | 418.8 | 2.3 |
– of which consultants and other R&D | 286.5 | 399.0 | 39.3 |
Employee benefits (corporate) | 300.0 | 552.6 | 84.2 |
Promotion and communication | 148.8 | 157.6 | 5.9 |
Consultancy and legal | 138.8 | 127.6 | -8.0 |
Depreciation and amortisation | 35.8 | 14.6 | -59.3 |
Share-based payments | 40.0 | 672.0 | 1,580.1 |
Other expenses | 275.6 | 355.0 | 28.8 |
Interest expense | 35.0 | 11.4 | -67.4 |
Balance Sheet and Share Count (m)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents (AUD K) | — | 548.2 | 138.8 | 617.3 | 1,332.1 |
Total current assets (AUD K) | — | — | 185.9 | 727.6 | 1,418.0 |
Total assets (AUD K) | — | — | 242.0 | 747.8 | 1,423.7 |
Short-term debt incl. leases (AUD K) | — | — | 42.5 | 13.1 | 7.2 |
Long-term debt (AUD K) | — | — | 0 | 0 | 0 |
Total debt (AUD K) | — | — | 42.5 | 13.1 | 7.2 |
Net debt / (net cash) (AUD K) | — | — | -96.3 | -604.2 | -1,324.9 |
Total liabilities (AUD K) | — | — | 465.6 | 351.4 | 225.4 |
Total equity (AUD K) | — | 451.6 | -223.7 | 396.4 | 1,198.3 |
Goodwill and intangibles (AUD K) | 0 | 0 | 0 | 0 | 0 |
Working capital (AUD K) | — | — | -279.8 | 376.2 | 1,192.6 |
Accumulated losses (AUD K) | — | -9,647.3 | -10,803.8 | -12,230.3 | -14,624.3 |
Shares on issue (m) | — | 148.9 | 172.0 | 305.1 | 409.0 |
Cash Flow
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Operating cash flow (AUD K) | -901.0 | -1,098.5 | -1,795.9 |
– incl. R&D incentive received (AUD K) | 280.3 | 231.6 | 311.1 |
Capex (AUD K) | 0 | 0 | 0 |
Free cash flow (AUD K) | -901.0 | -1,098.5 | -1,795.9 |
Investing cash flow (AUD K) | 16.0 | 0 | 0 |
Equity raised, net of costs (AUD K) | 503.0 | 1,606.6 | 2,523.8 |
Lease repayments (AUD K) | -27.5 | -29.4 | -13.1 |
Financing cash flow (AUD K) | 475.5 | 1,577.1 | 2,510.8 |
Dividends paid (AUD K) | 0 | 0 | 0 |
Buybacks (AUD K) | 0 | 0 | 0 |
Net change in cash (AUD K) | -409.5 | 478.6 | 714.8 |
Financial Ratios (x) and Returns & Leverage Ratios (%)
| Ratio | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Current ratio (x) | 0.40 | 2.07 | 6.29 |
Debt to equity (x) | n/m | 0.03 | 0.01 |
ROA (%) | — | -288.2 | -220.5 |
ROE (%) | n/m | n/m | -300.3 |
Cash burn cover (cash ÷ annual operating outflow, years) | 0.15 | 0.56 | 0.74 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia (AUD K) | 12.5 | 0 | 0 |
Rest of world (AUD K) | 0 | 0 | 0 |
Country Overview
| Country | Activity | Status |
|---|---|---|
China (Haikou, Hainan) | MC fermentation and supply (HGB) | Ongoing long-term supply partner |
India | Lyocell dissolution and spinning (Birla Cellulose); yarn and fabric (Paradise Textiles) | Ongoing |
United Kingdom | Initial washing/dewatering equipment trials | Completed FY2026 |
Europe (country not disclosed) | Washing-at-scale equipment trial | Completed FY2026 |
Europe (Codi Group); USA (Magnera) | Nonwovens/wipes trials | Deprioritised |
Australia (Western Australia) | Head office, onshored analytics, planned Pilot Facility | Expanding |
Share Price and Share Count (m)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.090 | 0.071 | 0.055 | 0.025 | 0.067 | 0.050 |
Shares on issue at 30 June (m) | — | — | 148.9 | 172.0 | 305.1 | 409.0 |
Implied market cap at 30 June (AUD Mn) | — | — | 8.2 | 4.3 | 20.4 | 20.4 |
Share Price History
| Period | Price move | Return |
|---|---|---|
1-year | A$0.067 → A$0.050 | -25.4% |
3-year | A$0.055 → A$0.050 | -9.1% |
5-year | A$0.090 → A$0.050 | -44.4% |
Since IPO (A$0.20, Oct 2017) | A$0.20 → A$0.050 | about -75% |
Valuation Multiples
| Multiple | Nanollose | Spinnova | Lenzing |
|---|---|---|---|
Market cap | ~A$20.4m | — | — |
Enterprise value | ~A$19.1m (market cap minus A$1.33m cash plus A$0.01m debt) | — | — |
P/E | n/m (loss) | n/m (loss) | n/m (FY2025 net loss) |
EV/EBITDA | n/m | n/m | — |
EV/Sales | n/m (nil revenue). Multiples.vc showed about 2,450× on a trailing A$9k revenue figure, which is not meaningful | n/m | — |
P/B | ~17.0× (A$20.4m ÷ A$1.20m) | — | — |
Fully diluted shares | ~488.5m (409.0m + 73.5m options + 6.0m rights) | — | — |
Class Details
| Class | Number | Exercise price | Expiry | Potential proceeds (AUD K) |
|---|---|---|---|---|
NC6OB (listed) | 29,405,000 | 0.05 | 6 Feb 2027 | 1,470 |
NC6OPT11 | 9,638,892 | 0.025 / 0.035 / 0.045 (tiered by year) | 30 Apr 2028 | ~337 (at 0.035) |
NC6OPT12 (CEO) | 15,000,000 | 0.07 | 14 Jul 2028 | 1,050 |
NC6OPT13 (CEO) | 15,000,000 | 0.10 | 14 Jul 2028 | 1,500 |
NC6OPT14 | 2,500,000 | 0.05 | 6 Feb 2027 | 125 |
NC6OPT16 | 1,000,000 | 0.066 | 3 Dec 2028 | 66 |
NC6OPT17 | 1,000,000 | 0.10 | 31 Jan 2029 | 100 |
Total | 73,543,892 | — | — | ~4648 |
Analyst Conclusions
Management guidance
No quantitative guidance has been given. The FY2027 operating objectives are:
-
Secure and fit out Western Australian premises.
-
Complete the equipment tender and disclose the Pilot Facility's cost, configuration and output.
-
Commission onshore analytical and processing equipment.
-
Complete larger-volume dewatering and washing trials.
-
Build, commission and run the Pilot Facility.
-
Advance dissolution validation in India.
-
Convert partner evaluations into formal commercial arrangements.
-
Pursue non-dilutive grant funding.
The FY2026 Annual Report outlook calls this a "year focused on delivery."
Consensus
None available (no coverage).
Bull case
-
Cheap option on a large market. An enterprise value of about A$19m buys a validated drop-in feedstock for an 8.4mt, US$20bn industry. Even a single royalty-bearing licence with a major such as Birla Cellulose, covering a small fraction of lyocell output, could justify a multiple of today's value. Licensing needs no Nanollose-funded industrial capex.
-
Technical de-risking is visible. The fourth spin removed partner pre-processing and the April 2026 lab process cut a stage while lifting efficiency by at least 80%. Equipment vendors have expressed confidence in scalability. The questions have shifted, as management says, "from invention to engineering," and the newly hired Tesla- and Sandvik-experienced engineers suit that phase.
-
Regulatory pull. EUDR compliance and brand deforestation pledges create urgency for non-forest feedstocks, while incumbents' existing assets make a drop-in solution the path of least resistance. The unsolicited 50kg brand request signals real demand.
Bear case
-
Funding arithmetic. Cash of A$1.33m against a burn of about A$1.5–1.8m a year before capex, plus an undisclosed Pilot Facility cost that management admits exceeds existing reserves. Raising at about A$0.05 means significant dilution on top of the 2.4× share-count increase since FY2024, and going-concern uncertainty persists.
-
Execution and track record. Four pilot spins and about nine years since IPO have produced no binding offtake or licence. The strategy changed twice within FY2026, and laboratory-scale gains have historically failed to translate at pilot scale across the biomaterials sector. The economics of bacterial-cellulose fermentation at commodity cost remain unproven, and management concedes it lacks the operating data.
-
Governance and counterparty concentration. A three-person board without a clearly independent director, related-party service providers, and dependence on one Chinese supplier and one Indian spinner (who co-owns key IP) weaken negotiating leverage and oversight just as the company enters a capital-intensive phase.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | Why it matters |
|---|---|---|
| By 31 Oct 2026 | September-2026 quarterly / 4C | Cash burn, equipment arrival, site status |
| By 12 Nov 2026 | AGM | Board renewal (independent director appointment?), placement capacity resolutions (ASX Listing Rule 7.1A) |
| H2 CY2026 | Pilot Facility cost and configuration disclosure | Sizes the funding requirement; key valuation input |
| H2 CY2026 | Western Australian premises secured | Execution milestone |
| H2 CY2026 – H1 CY2027 | Larger-volume dewatering and washing trials; dissolution validation in India | Technical de-risking |
| H2 CY2026 | Paradise Textiles yarn and fabric output from the fourth spin; brand feedback | Demand validation |
| H2 CY2026 | 50kg specialised-grade delivery to the international brand | Brand relationship signal |
| Mar-2027 quarter | FY2026 R&D Tax Incentive refund | Non-dilutive cash (about A$0.3–0.4m expected) |
| 6 Feb 2027 | NC6OB option expiry ($0.05) | Up to A$1.47m if in-the-money; at-the-money today |
| CY2027 | Capital raise, grant award, or partner-funding announcement | Determines dilution and timeline |
| Ongoing | Any binding licence, JV, offtake or strategic transaction | The single largest value catalyst |
Concluding analyst verdict
Nanollose is a binary, pre-revenue technology option. Its investment case has improved materially in quality over the past 18 months, but its financial capacity to deliver remains thin.
On the positive side, the company now has a clearer strategy than at any point since its 2017 IPO. It has narrowed to a single flagship pathway (Nullarbor), a capital-efficient end-state (licensing into existing lyocell plants), and a concrete near-term objective (a self-controlled Western Australian Pilot Facility). The fourth Birla Cellulose pilot spin in February 2026 provided the most convincing evidence yet that microbial cellulose can act as a drop-in, incremental feedstock. The subsequent laboratory process improvement, if it holds at pilot scale, addresses the historic Achilles' heel of bacterial cellulose: processing cost and consistency. Management's tone is notably candid, setting measurable markers and openly listing what has not been achieved. Structural tailwinds from the EU Deforestation Regulation and brand traceability commitments are genuine.
Against this, the balance sheet cannot carry the plan. With A$1.33m of cash at 30 June 2026, an underlying burn of about A$1.5m a year and a facility of undisclosed cost, Nanollose will almost certainly need to raise material new capital within the next two to three quarters. At the current share price that implies further heavy dilution, unless non-dilutive grants or a partner co-investment materialise. Governance is below best practice for a company entering a capital-intensive phase. The absence of any binding commercial agreement, four years after the first pilot spin, keeps commercial risk high.
Verdict. Treat this as speculative. The probability-weighted value hinges on three disclosures in the next 6–12 months: the Pilot Facility cost, the funding structure, and evidence of a licence-grade counterparty commitment (most plausibly Birla).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Appointed / tenure | Prior roles | Education |
|---|---|---|---|---|
Dr Wayne Best | Executive Chairman | Executive service agreement from 10 Apr 2018; full-time at Nanollose since 2018 | About 40 years in organic chemistry. Founder and MD of Epichem Pty Ltd (contract research/drug discovery, 14 years). Chemistry Centre (WA), where he formed the Medicinal & Biological Chemistry Section (10 years). ICI Australia Research Group (4.5 years). Adjunct Associate Professor at Murdoch University and UWA | BSc (Hons), PhD Organic Chemistry (UWA); DIC (Imperial College); FRACI; GAICD |
Andrew Moullin | Managing Director & CEO | Since 14 Jul 2025 | Commercial Projects & Senior Corporate Lawyer, Iluka Resources. Roles at DLA Piper, Macro Metals, Fivemark Partners, CLSA. Founded several businesses with exits | LLB; BA (Psychology); Grad Dip Applied Finance; GAICD; FGIA |
Winton Willesee | Non-Executive Director; Joint Company Secretary | Since 18 Oct 2017 | More than 20 years in Australian capital markets. Current NED of One Click Group (ASX:1CG) and KTEK Aerosystems (ASX:KTK, from 20 Mar 2026). Former NED of Neurotech International and Bridge SaaS | BBus, DipEd, PGDipBus, MCom; FFin; CPA; GAICD; FGIS/FCIS |
Heidi Beatty | Non-Executive Director (resigned) | 8 Jul 2019 – 1 Apr 2026 | Founder of Crown Abbey Ltd (consultancy); 10 years at Johnson & Johnson (Europe/US) | BSc Chemistry (University of York) |
Timothy Barker | Joint Company Secretary | Since Apr 2025 | Not detailed | LLB (English and French Law); MSc International Business Management |
Danielle Nardini | Operations & Engineering Manager (not KMP) | Appointed Jun 2026; started Jul 2026 | More than 16 years in engineering and operations. Sandvik (scale-up of battery-electric mining systems); Sustainability Principal at Sandfire Resources | Master's and BSc in Industrial Engineering |
Peter Hillier | Process engineering consultant | Engaged Aug 2026 | Founder and lead process engineer; more than 15 years of scale-up experience | — |
Dr Jacob Brown | Chemical engineering consultant | Engaged Aug 2026 | Former senior chemical engineer at Tesla (electrode active materials); founder of a metal-extraction start-up | PhD Chemical Engineering (Cambridge) |
Scott Williams | Corporate Advisor (Fiftyone Capital) | 12-month mandate from Aug 2025 | Founder and principal of Fiftyone Capital (est. 2018) | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Name | Cash salary/fees | Superannuation | Leave | Options (SBP) | Performance rights (SBP) | Total | Fixed % | At-risk % |
|---|---|---|---|---|---|---|---|---|
Wayne Best | 241,667 | 29,000 | 109 | 0 | 0 | 270,776 | 100 | 0 |
Andrew Moullin | 257,669 | 30,920 | 11,641 | 518,165 | 54,942 | 873,337 | 34 | 66 |
Winton Willesee | 51,667 | 0 | 0 | 0 | 0 | 51,667 | 100 | 0 |
Heidi Beatty | 45,000 | 0 | 0 | 25,179 | 0 | 70,179 | 64 | 36 |
Total | 596,003 | 59,920 | 11,750 | 543,344 | 54,942 | 1,265,959 | — | — |
Directors' Remuneration (Annual)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total KMP remuneration (AUD K) | 316.3 | 374.2 | 1,266.0 |
Executive Leadership Team by Person
| Person | Change |
|---|---|
Wayne Best | A$225k → A$267.5k from 1 Jul 2025, then cut to A$112.5k from 1 May 2026 |
Andrew Moullin | A$267k plus superannuation |
Winton Willesee | A$60k → A$35k from 1 Mar 2026 |
Governance Detail
| Related entity | Linked director(s) | Service | Amount paid |
|---|---|---|---|
Epichemistry Pty Ltd | Best and Willesee | Chemical research and analysis | A$17,100 |
Azalea Corporate Services | Willesee | Corporate, accounting and company secretarial services | A$135,600 |
Major Shareholders
| Holder | Shares | % at notice | Notice date |
|---|---|---|---|
WACC Pty Ltd ATF Flagship Fund | 25,019,970 | 8.21 | 21 May 2025 |
Azalea Family Holdings Pty Ltd (Willesee family trust) | 24,858,006 (24,258,006 at Aug 2026) | 8.15 | 26 May 2025 |
Wayne Morris Best | 22,400,000 | 7.35 | 26 May 2025 |
ConBrio Beteiligungen AG | 20,625,000 | 6.77 | 20 May 2025 |
Fiftyone Capital Pty Ltd | Described as an existing substantial shareholder; it exercised 30m options in FY2026. Exact current holding not publicly disclosed in sources reviewed | — | — |
Dutch Ink (2010) Pty Ltd | Held 33.4m NC6OPT11 options at Aug 2025. Since 1 April 2026 these options have largely been converted (NC6OPT11 options outstanding fell from 111.7m to 9.6m), so a material shareholding is likely but unconfirmed | — | — |
Competitive Landscape
Key Competitors
| Competitor | Country / listing | Technology / position | Latest reported scale | Relative positioning vs Nanollose |
|---|---|---|---|---|
Lenzing AG | Austria / Vienna (LNZ) | Incumbent lyocell, modal and viscose (TENCEL™, ECOVERO™, VEOCEL™) from wood pulp; integrated dissolving pulp in Brazil | FY2025 revenue about €2.6bn (down 2.3%); adjusted EBITDA €425.6m; net loss €135.2m; about 17,700 FTE; 61% of revenue from Asia | Potential licensee or customer as much as competitor; huge scale advantage; wood-pulp based |
Birla Cellulose (Grasim Industries) | India / NSE-BSE (via Grasim) | Major global MMCF producer (viscose, lyocell); Nanollose's spinning partner | — | Partner and most likely licensee; could develop alternatives internally |
Sateri (RGE Group) | China / private | Large viscose and lyocell producer; recycled-feedstock initiatives | — | Incumbent; potential licensee |
Tangshan Sanyou | China / Shanghai | Large viscose producer | — | Incumbent |
Kelheim Fibres | Germany / private | Specialty viscose for hygiene and nonwovens | — | Relevant to the (now deprioritised) Nufolium market |
Spinnova Plc | Finland / Nasdaq Helsinki (SPINN) | Mechanical wood/waste-to-fibre with no dissolving chemicals | FY2025 revenue €344k (2024: €762k); net loss €40.7m; cash and investments €44.4m; 68 granted patents. Sources differ on operating loss: €41.3m (FashionUnited) vs €23.8m (Quartr summary). The gap likely reflects impairment classification | Closest listed next-gen fibre peer; better funded but also pre-commercial and restructuring |
Circulose (formerly Renewcell) | Sweden / private | Textile-to-textile recycled dissolving pulp; drop-in for viscose and lyocell | — | Direct competitor for "alternative feedstock" slots in MMCF lines |
Infinited Fiber Company | Finland / private | Textile-waste regenerated fibre (carbamate process) | — | Competes for brand partnerships; requires new process plant |
Evrnu | USA / private | Recycled-cotton regenerated fibre (NuCycl) | — | Brand-facing competitor |
Polybion | Mexico / private | Bacterial-cellulose biomaterials (leather alternatives) | — | Direct technology analogue in the deprioritised leather segment |
Modern Meadow / Bolt Threads and other biomaterials players | USA / private | Biofabricated materials | — | Compete for brand sustainability budgets |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Nanollose FY2026 (AUD) | Spinnova FY2025 (EUR) | Lenzing FY2025 (EUR) |
|---|---|---|---|
Revenue | 0 | 0.344 | ~2,600 |
Revenue growth (%) | n/m | -54.9 | -2.3 |
EBITDA margin (%) | n/m | n/m | 16.4 (adjusted) |
Net result | -2.39 | -40.7 | -135.2 |
Cash | 1.33 | 44.4 (incl. current investments) | Liquidity ~910+ |
R&D intensity | n/m (pre-revenue) | n/m | — |



